BridgeBio Pharma Inc (NAS:BBIO)
$ 27.94 0.18 (0.65%) Market Cap: 5.23 Bil Enterprise Value: 6.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

BridgeBio Pharma Inc and Eidos Therapeutics Inc at Cowen HealthCare Conference Transcript

Mar 04, 2020 / 02:20PM GMT
Release Date Price: $31.06 (-4.69%)
C.J. Zopf
Cowen and Company - Analyst

All right (technical difficulty) equity research here. So BridgeBio has assembled a portfolio of over 20 programs spanning genetic diseases, dermatology and targeted oncology with some genetic drivers as well.

This sounds like a lot, but the portfolio is supported by a unique structure as well as the Company's strategy of jumping on science that they either have a lead on because they were willing to start earlier, or because of their connections to academia that may give them some advantage there as well. Here to tell us more today, Senior Vice President of BridgeBio, Tom Trimarchi.

Tom Trimarchi
BridgeBio Pharma, Inc. - SVP

All right, great, thank you. Again, Tom Trimarchi, Senior VP BridgeBio. First I want to thank all of you for being here in the room with us. I know it's the last day of what was a long and hopefully productive conference in what already feels like along week and it's only Wednesday. But really appreciate you all being here.

Before I dig into the presentation I just want to say a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot